This summary highlights the experiences, results and actions from
the implementation of the Rapid Assessment Tool for Sexual and
The tool – developed by IPPF, UNFPA, WHO, UNAIDS, GNP+, ICW and Young Positives in
2009 – supports national assessments of the bi-directional linkages
between sexu...al and reproductive health (SRH) and HIV at the policy,
systems and services levels. Each country that has rolled out the
tool has gathered and generated information that will help to
determine priorities and shape national plans and frameworks for
scaling up and intensifying linkages. Country experiences and best
practices will also inform regional and global agendas.
more
This fourth WHO report on neglected tropical diseases (NTDs) reviews the progress made towards achieving the Roadmap targets for 2020, noting the remaining challenges, then looks beyond 2020 to evaluate the changing global health and development landscape, considering the implications of integrating... these diseases into the broader 2030 Agenda for Sustainable Development.
more
With a focus on Pakistan and Nigeria’s most vulnerable communities, this report provides insight about the role that community push-back is playing in the transmission of the polio virus and how the Global Polio Eradication Initiative (GPEI) can mitigate these social risks to reach every missed ch...ild.
more
Le projet a pour objectif sectoriel de contribuer à la réalisation des objectifs de développement du millénaire dans le domaine de la santé au Bénin : réduction de la mortalité infantile, amélioration de la santé maternelle, lutte contre les IST/VIH/SIDA, le paludisme et aut...res maladies. Les objectifs spécifiques sont les suivants: i) améliorer l’offre et la qualité des services de santé ; et ii) augmenter l’utilisation des services de santé. Le projet comprend trois composantes : i) amélioration de l’accessibilité à des services de santé de qualité; ii) promotion de la santé materno-infantile et lutte contre la maladie et iii) Gestion du projet.
more
Chapter 9: Public health guide for emergencies
Lancet Global Health Volume 7, Issue 1, January 2019, Pages e81-e95
The 2018 Humanitarian Response Plan (HRP) aimed to assist 10.5 million people with direct assistance and 11.2 million people with improved access to basic services. In an effort to meet humanitarian needs, humanitarian partners provided various types of humanitarian life-saving and life-sustaining... assistance and services to a monthly average of 5.5 million people during 2018. Of the 5.5 million people reached on average on a monthly basis, 2.1 million were people living in areas of high severity of need, as measured through the inter-sector severity scale.
In 2018, these efforts were funded by international support to Syria with $2.19 billion raised (65 per cent of HRP requirements) by the end of the year – more than any previous year. Thanks to this generous support, humanitarian organisations in Syria continued to deliver a massive humanitarian response to people in need with multiple humanitarian crises unfolding across the country.
more
The DHS report itself explains the purpose was, “to obtain and provide information on basic indicators of social progress including fertility, childhood mortality, reproductive and child health, nutritional status of children, and awareness of HIV/AIDS and other health-related issues” in PNG. Th...is is important because a DHS then provides the evidence base for PNG officials themselves to track progress in PNG over time, compare trends with other comparable countries, and then allocate financial and human resources to where they are needed most.
more
22 Sept. 2021
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi...ve role in restricting fair access to a life-saving health product. This report focuses on six leading vaccine developers, AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.
Available in Arabic, English, French, German and Spanish
more